Discovery Life Sciences Acquires In Vitro ADMET Laboratories (IVAL)
December 2, 2021
Discovery Life Sciences has acquired Maryland-based In Vitro ADMET Laboratories (IVAL) to add the world’s largest hepatocyte inventory and leading in vitro ADMET expertise. IVAL founder Albert P. Li, Ph.D. will join Discovery as Chief Scientific Officer of Pharmacology and Toxicology as Discovery expands its biospecimen and biomarker service capabilities to better support drug metabolism, toxicology, and pharmacology testing for pharma customers.
- Buyers
- Discovery Life Sciences
- Targets
- In Vitro ADMET Laboratories (IVAL)
- Industry
- Healthcare Services
- Location
- Maryland, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Discovery Life Sciences Acquires Gentest Business from Corning Incorporated
April 5, 2022
Biotechnology
Discovery Life Sciences has acquired the Gentest business unit from Corning Incorporated to expand its in vitro ADME and toxicology reagent and services offering. The deal complements Discovery’s recent acquisition of In Vitro ADMET Laboratories (IVAL) and strengthens its hepatocyte, microsome and ADME-related product and contracted research capabilities for pharmaceutical and life sciences customers.
-
BioIVT Acquires XenoTech from Sekisui Chemical
September 12, 2022
Biotechnology
BioIVT has acquired XenoTech, a Kansas City–based provider of ADME‑Tox in vitro models and contract research services, from Sekisui Chemical. The acquisition expands BioIVT's hepatic product portfolio and ADME/DMPK capabilities to better support biopharma customers' preclinical testing needs. Financial terms were not disclosed.
-
Eurofins Discovery Acquires DiscoveryBioMed
July 5, 2022
Biotechnology
Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.
-
Discovery Life Sciences Acquires QualTek Molecular Laboratories
May 5, 2019
Healthcare Services
Discovery Life Sciences (based in Huntsville, Alabama) has acquired QualTek Molecular Laboratories, a provider of CAP/CLIA-accredited and GLP-capable immunohistochemistry (IHC) laboratories in California and Pennsylvania. The acquisition expands Discovery's histopathology and IHC assay development capabilities and integrates QualTek's services with Discovery's biospecimen, sequencing, flow cytometry and multiomic annotation offerings to accelerate biomarker validation and drug/diagnostic development.
-
BioIVT Acquires Valley Biomedical Products & Services
June 28, 2021
Medical Devices
BioIVT, a provider of research models and value-added research services, has acquired Valley Biomedical Products & Services, an FDA-registered manufacturer of in vitro diagnostics, sera, plasma and reagents based in Winchester, Virginia. The acquisition will expand BioIVT’s capabilities in IVD manufacturing and cell & gene therapy support by combining Valley Biomedical’s reagent and blood-product manufacturing with BioIVT’s donor centers and specimen services; BioIVT will continue operating the Winchester facility and retain its staff.
-
Agilent Technologies Acquires Avida Biomed
January 4, 2023
Biotechnology
Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.